More tools:Markets·Screener·Research·Chat

Medicinova, Inc. (MNOV) Financial Statements

Medicinova, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SNG8P4
XNAS · usd
1.76▲ 0.01 (0.57%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.75
Day's Range1.65 – 1.76
52-Week Range1.17 – 1.96
Volume137.7K
Avg Volume44.6K
Share Statistics
Shares Outstanding
Employees6
ExchangeXNAS
Listed2006-12-07
Share count as of August 11, 2026
Loading Income Statement…
Key questions about Medicinova, Inc. (MNOV)
What is Medicinova, Inc.'s Market Cap?
Medicinova, Inc.'s Market Cap is $86.6M, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s Enterprise Value?
Medicinova, Inc.'s Enterprise Value is $61.2M, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s Price / Sales?
Medicinova, Inc.'s Price / Sales is 94.1×, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s EV / Revenue?
Medicinova, Inc.'s EV / Revenue is 66.5×, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s EV / EBITDA?
Medicinova, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s Revenue (TTM)?
Medicinova, Inc.'s Revenue (TTM) is $920.5K, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s Net Income (TTM)?
Medicinova, Inc.'s Net Income (TTM) is -$10.8M, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s EBITDA?
Medicinova, Inc.'s EBITDA is -$11.8M, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s Diluted EPS (TTM)?
Medicinova, Inc.'s Diluted EPS (TTM) is -0.22, based on as-reported figures from SEC (XBRL) filings.
What is Medicinova, Inc.'s EBITDA Margin?
Medicinova, Inc.'s EBITDA Margin is -1285.3%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
YoY growth+240.6%———
Operating expenses:
Costs of services
Research, development and patents
General and administrative
Total operating expenses
% of revenue654.3%1616.6%2138.0%2841.7%
Operating loss
% of revenue-554.3%-1516.6%-2038.0%-2741.7%
Interest income
Other income (expense), net
Net loss
% of revenue-504.8%-1383.1%-1846.8%-2473.6%
Basic net loss per common share
Diluted net loss per common share